Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Baxter to $48 from $50 and keeps an Outperform rating on the shares, which were also added to the firm’s "Tactical Outperform" list as the firm made a number of changes to its lists as part of its Q1 earnings preview for the MedTech, Life Science Tools and Diagnostics group.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BAX: